Published in Blood on May 15, 1989
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol (1996) 2.85
Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J Exp Med (1994) 2.72
Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci U S A (1995) 2.30
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
Virus escape from CTL recognition. J Exp Med (1994) 1.97
An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. J Virol (1991) 1.80
Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med (1995) 1.78
Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc Natl Acad Sci U S A (1996) 1.68
Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol (1993) 1.35
Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J Virol (1993) 1.33
Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein. Proc Natl Acad Sci U S A (1991) 1.26
Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci U S A (1997) 1.25
Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J Clin Invest (1997) 1.21
Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats. J Virol (1992) 1.10
Expression of Mycobacterium tuberculosis and Mycobacterium leprae proteins by vaccinia virus. Infect Immun (1990) 0.89
Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector. Vaccine (2009) 0.89
Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity. Clin Exp Immunol (1993) 0.87
Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. J Virol (2004) 0.85
Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes. J Virol (1992) 0.84
Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses. Front Immunol (2013) 0.82
Multispecific and heterogeneous recognition of the gag protein by cytotoxic T lymphocytes (CTL) from HIV-infected patients: factors other than the MHC control the epitopic specificities. Clin Exp Immunol (1994) 0.80
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med (1995) 8.15
Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med (1989) 7.52
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood (1980) 3.51
Iron and the sex difference in heart disease risk. Lancet (1981) 3.45
Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J (2008) 3.36
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet (1993) 3.03
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst (1985) 2.95
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Arrangement of late RNAs transcribed from a 7.1-kilobase EcoRI vaccinia virus DNA fragment. J Virol (1984) 2.48
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology (1978) 2.41
Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med (1992) 2.33
Immune response after splenectomy. Lancet (1978) 2.31
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Factor concentrates for treatment of hemophilia: which one to choose? Blood (1989) 2.16
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol (2000) 2.04
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) (2002) 1.96
Cough and asthma in children. Pediatr Ann (1996) 1.95
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes. J Exp Med (1975) 1.86
Influenza virus infection in nude mice. J Infect Dis (1976) 1.85
An acute effect of cigarette smoking on platelet function. A possible link between smoking and arterial thrombosis. Circulation (1973) 1.84
Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol (2001) 1.80
Serum theophylline levels in asthmatic children after oral administration of two slow-release theophylline preparations. Arch Dis Child (1978) 1.79
Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol (1989) 1.77
Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys (1998) 1.72
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol (2001) 1.72
HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol (1995) 1.69
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med (1999) 1.69
Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer (1999) 1.68
Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev (1993) 1.66
Timing of events in normal swallowing: a videofluoroscopic study. Dysphagia (2000) 1.64
Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression. Gene (1986) 1.64
Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood (1990) 1.64
Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum (2004) 1.63
Aetiology of AIDS--antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature (1984) 1.63
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
Organization of six early transcripts synthesized from a vaccinia virus EcoRI DNA fragment. J Virol (1984) 1.62
Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol (1999) 1.61
Epidemiology and clinical impact of hepatitis D virus (delta) infection. Hepatology (1985) 1.60
High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis (1995) 1.58
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med (1997) 1.56
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.55
Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer (1972) 1.55
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 1.53
Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (1994) 1.51
Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med (1988) 1.51
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med (1997) 1.50
"Chronic Epstein-Barr virus infection" syndrome and polymyalgia rheumatica. J Rheumatol (1988) 1.50
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Inhibition of lymphocyte stimulation by measles virus. J Immunol (1975) 1.47
Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B. Ann Intern Med (1973) 1.46
European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol (2001) 1.44
Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye (Lond) (1993) 1.44
Structural displacements in normal swallowing: a videofluoroscopic study. Dysphagia (2000) 1.43
Antioxidants and coronary heart disease. Lancet (1991) 1.43
On the antioxidant properties of erythropoietin and its association with the oxidative-nitrosative stress response to hypoxia in humans. Acta Physiol (Oxf) (2014) 1.43
Transfusion transmission of human T-lymphotropic virus types I and II: lessons to be learned from look-back investigations and implications for patient counseling. Transfusion (1993) 1.42
Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol (1987) 1.42
Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis (1997) 1.41
Reactive histiocytic disorders. Am J Clin Pathol (1993) 1.41
A clinical comparison of beclomethasone dipropionate delivered by pressurised aerosol and as a powder from a rotahaler. Arch Dis Child (1979) 1.41
n-3 fatty acids and cellular aspects of atherosclerosis. Arch Intern Med (1989) 1.39
Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis (2004) 1.39
Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. Am J Epidemiol (1990) 1.38
Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol (2001) 1.37
Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst (1974) 1.36
Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama. Proc Natl Acad Sci U S A (1990) 1.36